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ARTICLE
Accessibility of Targeted DHPR Sites to Streptavidin and Functional 
Effects of Binding on EC Coupling
Nancy M. Lorenzon and Kurt G. Beam
Department of Physiology and Biophysics, University of Colorado Health Sciences Center, Aurora, CO 80045
In skeletal muscle, the dihydropyridine receptor (DHPR) in the plasma membrane (PM) serves as a Ca2+ channel 
and as the voltage sensor for excitation–contraction (EC coupling), triggering Ca2+ release via the type 1 ryano-
dine receptor (RyR1) in the sarcoplasmic reticulum (SR) membrane. In addition to being functionally linked, 
these two proteins are also structurally linked to one another, but the identity of these links remains unknown. 
As an approach to address this issue, we have expressed DHPR α1S or β1a subunits, with a biotin acceptor domain 
fused to targeted sites, in myotubes null for the corresponding, endogenous DHPR subunit. After saponin permea-
bilization, the  60-kD streptavidin molecule had access to the β1a N and C termini and to the α1S N terminus and 
proximal II–III loop (residues 671–686). Steptavidin also had access to these sites after injection into living 
myotubes. However, sites of the α1S C terminus were either inaccessible or conditionally accessible in saponin-
permeabilized myotubes, suggesting that these C-terminal regions may exist in conformations that are occluded 
by other proteins in PM/SR junction (e.g., RyR1). The binding of injected streptavidin to the β1a N or C terminus, 
or to the α1S N terminus, had no effect on electrically evoked contractions. By contrast, binding of streptavidin to 
the proximal α1S II–III loop abolished such contractions, without affecting agonist-induced Ca2+ release via RyR1. 
Moreover, the block of EC coupling did not appear to result from global distortion of the DHPR and supports the 
hypothesis that conformational changes of the α1S II–III loop are necessary for EC coupling in skeletal muscle.
INTRODUCTION
In skeletal muscle, bidirectional signaling occurs between 
the dihydropyridine receptor (DHPR; a voltage-gated 
calcium channel composed of a pore-forming α1S subunit 
and auxiliary subunits α2-δ, β1a, and γ), and the ryano-
dine receptor (RyR1; a calcium release channel). Depo-
larization of the plasma membrane, where DHPRs are 
located, causes transmission of an orthograde signal from 
the DHPRs to the RyRs in the SR, resulting in calcium 
release (Rios and Brum, 1987; Tanabe et al., 1987; Garcia 
et al., 1994; Dirksen and Beam, 1999). This orthograde, 
excitation–contraction (EC) coupling signal is indepen-
dent of the entry of extracellular calcium. In addition, 
retrograde signaling exists whereby the association with 
RyR1 increases the magnitude of the voltage-gated Ca2+ 
current carried per DHPR (Nakai et al., 1996).
In addition to functional coupling of the DHPR and 
RyR1, structural coupling of these two proteins has been 
suggested from freeze-fracture studies of the plasma 
membrane, which reveal that DHPRs occur in “tetrads,” 
groups of four intramembranous particles that are 
arranged in ordered arrays (Franzini-Armstrong and 
Kish, 1995; Beam and Franzini-Armstrong, 1997; Protasi, 
2002). The individual DHPRs within a tetrad are located 
in exact correspondence to the four subunits of RyR1 
(Franzini-Armstrong and Kish, 1995; Block et al., 1988). 
The arrangement of DHPRs into tetrads is dependent 
on the presence of RyR1 (Protasi et al., 1998, 2000), 
implying that the DHPR and RyR1 are linked.
To understand skeletal-type EC coupling it is essen-
tial (a) to identify the regions of the DHPR that link 
it, directly or indirectly, to RyR1, and (b) to establish 
which of these regions may undergo voltage-driven con-
formational changes that are necessary for propagating 
the EC coupling signal. Toward this end, one approach 
has been to study cDNAs expressed in myotubes. Such 
approaches have shown that the α1S II–III loop critical 
domain (Nakai et al., 1998; Kugler et al., 2004) and the 
β1a C terminus are important for skeletal-type EC cou-
pling (Beurg et al., 1999; Ahern et al., 2001; Sheridan 
et al., 2003), and that the α1S C terminus is impor-
tant for targeting DHPRs to plasma membrane/SR 
junctions (Flucher et al., 2000b; Proenza et al., 2000). 
Additionally, in vitro biochemical studies have revealed 
that RyR1 has the ability to bind fragments of the 
α1S II–III loop and C terminus (Proenza et al., 2002), 
as well as the β1a C terminus (Cheng et al., 2005). How-
ever, considerable uncertainty remains as to whether 
these binding interactions also occur in vivo. Moreover, 
none of the studies to date have been able to distin-
guish whether the identifi  ed regions are involved in 
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static interactions or undergo dynamic rearrangements 
during EC coupling.
As a new approach, we have begun to use cDNA con-
structs encoding a consensus sequence for metabolic 
biotinylation fused to sites of the DHPR. Previously, we 
employed this approach to demonstrate that after fi  xa-
tion and Triton permeabilization of myotubes express-
ing these constructs, the  60-kD molecule streptavidin 
has access to many sites of DHPRs that are inserted into 
fully assembled, plasma membrane/SR junctions, but 
that α1S C-terminal regions may be occluded by RyR1 
(Lorenzon et al. 2004).
The goal of the present work was to extend these 
studies to nonfi  xed myotubes, both to determine the pat-
tern of streptavidin accessibility under conditions closer 
to those in vivo and to determine whether the binding 
of streptavidin interferes with the function of the DHPR 
as calcium channel and voltage sensor for EC coupling. 
We have found that in nonfi  xed, saponin-permeabilized 
cells, streptavidin has access to all those DHPR sites pre-
viously found to be accessible in fi  xed cells. However, 
α1S C-terminal sites display a pattern of increased acces-
sibility in nonfi  xed cells, suggesting that the C terminus 
exists in at least two conformations, one of which is 
closely apposed to RyR1. When injected into living myo-
tubes, streptavidin was able to bind to the N and C ter-
mini of β1a and to the N terminus of α1S, but this binding 
did not affect electrically evoked contractions. By contrast, 
electrically evoked contractions were abolished when 
injected streptavidin bound to the proximal portion of 
the α1S II–III loop, consistent with a model in which de-
polarization causes a rearrangement of the II–III loop 
such that the critical domain activates RyR1. These data 
represent the most direct evidence to date that a con-
formational change of the α1S II–III loop is important 
for EC coupling.
MATERIALS AND METHODS
cDNA Constructs
The experiments described here made use of cDNA constructs 
(Fig. 1) that contained sequence for a biotin acceptor domain 
(BAD) of either 70 or 97 amino acids. The BAD sequence was 
excised from the PinPoint Xa-1 expression vector (Promega), 
which encodes a domain of a transcarboxylase subunit from 
Propionibacterium shermanii (PSTCD; PDB code 1DCZ; Reddy et al., 
2000). A previous publication (Lorenzon et al., 2004) described 
the construction of the expression plasmids for YFP-β1a-BAD, 
BAD-β1a-YFP, BAD-α1S-YFP, α1S(671-BAD-686)-YFP (previously des-
ignated α1S(I-II)-BAD-(III-IV)-YFP), YFP-α1S1667-BAD (previously 
designated YFP-α1Sshort-BAD), and YFP-α1S1860-BAD (previously 
designated YFP-α1Slong-BAD). We also analyzed YFP-α1S(1667-BAD) 
1860, in which the BAD was inserted between α1S C-terminal 
residue 1667 and the downstream α1S residues 1668–1860. To 
make this cDNA plasmid, PCR was used to introduce KpnI sites 
at the start and end of the 70-aa BAD from the PinPoint Xa-1 
vector (forward primer G  G  G  G  T A  C  C  G  A  G  G  G  C  G  A  G  A T  T  C  C  C  G  C  T  C  ; 
reverse primer C  C  G  G  T  A  C  C  C  G  A  T  C  T  T  G  A  T  G  A  G  A  C  C  C  T  G  A  C  C  ). 
A separate PCR reaction was used to remove a KpnI restriction 
site at the distal α1S C terminus (residue 1860) and introduce a 
new KpnI site after residue 1667 (forward primer G  C  C  A  A  T  G  C  -
C  A  A  G  G  T A  C  C  T A T  G  G  C  A  A  C  A  G  C  A  G  C  A  A  C  C  A T A  G  ; reverse primer 
A  T  C  C  C  G  G  G  C  C  C  G  C  G  C  T  A  C  C  G  T  C  G  A  C  T  G  G  T  C  A  ). The plasmids 
were cut with KpnI, and then the appropriate plasmid fragments 
were ligated to produce YFP-α1S(1667-BAD)1860. Restriction digests 
and sequencing were used to verify the construct.
Expression of cDNA
Primary cultures of myotubes isolated from newborn dysgenic 
(α1S-null) or β1-null mice were prepared as described previously 
(Beam and Franzini-Armstrong, 1997). Myoblasts were plated on 
ECL-coated (Upstate Biotechnology) glass-bottom (MatTek), or 
primaria plastic (BD Biosciences) 35-mm culture dishes. Myo-
tubes were grown for 6–7 d in a humidifi  ed 37°C incubator with 
5% CO2. Approximately 1 wk after plating, myotubes were micro-
injected (Tanabe et al., 1988) in a single nucleus with a cDNA 
construct (5–100 ng/μl). After injection, the cells were changed 
into a medium in which the biotin present in the 2% horse serum 
was supplemented with an additional 1 μM biotin.
NeutrAvidin Staining and Imaging
2 d after injection, myotubes were washed with an “internal” solu-
tion containing (in mM) 140 Cs-aspartate, 10 Cs2-EGTA, 5 MgCl2, 
and 10 HEPES, pH to 7.4 with CsOH. The myotubes were perme-
abilized with saponin (12 μg/ml in internal solution) for 30 s, 
and then exposed for 30 min in the dark to a 1:2,000 dilution (in 
internal solution) of NeutrAvidin-tetramethylrhodamine (Molec-
ular Probes), hereafter referred to as “streptavidin.” The cells 
were washed twice with internal solution, fi  xed with 4% parafor-
maldehyde in PBS for 20 min, and then imaged with an Axiovert/
LSM 510 META laser-scanning confocal microscope (Carl Zeiss 
MicroImaging, Inc.). Excitation/emission parameters for each 
fl  uorophore were as follows: YFP, 488 nm excitation, 488/543 nm 
dual dichroic, 505–530 nm band-pass emission fi  lter; rhodamine, 
543 nm excitation, 488/543 nm dual dichroic, 560 nm long-pass 
emission fi  lter. Cells were viewed with 40× (1.3 NA) or 63× (1.4 NA) 
oil immersion objectives.
Evoked Contractions and Streptavidin Injection
Myotubes were bathed in a rodent Ringers solution containing 
(in mM) 146 NaCl, 5 KCl, 2 CaCl, 1 MgCl2, 10 HEPES, 11 glucose 
(pH to 7.4 with NaOH) and tested for electrically evoked con-
tractions (extracellular stimulation 100 V, 10–20 ms). Cells that 
produced robust contractions were then bathed in Ringers solu-
tion containing N-benzyl-p-toluene sulphonamide (BTS; 10 μm) 
for 5–10 min to block contractions during subsequent micro-
injection with streptavidin (1 mg/ml). The cells were rinsed 
twice with culture medium and returned to the tissue culture 
incubator for at least 2 h. The identifi  ed myotubes were then 
retested for evoked contractions under the same conditions as 
before streptavidin injection. Records of contractions were ob-
tained by measuring the movement of an identifi  able portion of 
a myotube across the visual fi  eld from confocal images acquired 
at a rate of 11 Hz.
Calcium Transients and Streptavidin Injection
To analyze intracellular Ca2+ transients in response to membrane 
depolarization or to direct ryanodine receptor activation, intact 
myotubes were loaded with the fl  uorescent calcium indicator 
dye Fluo-3 AM. Before imaging, myotubes were washed free 
of the culture medium with rodent Ringer and exposed to the 
dye (5 μM in rodent Ringer) for 1 h at 37°C. Calcium tran-
sients were recorded in response to membrane depolarization by 
80 mM KCl or RyR1 activation by 0.5 mM 4-chloro-m-cresol 
(4-CmC), which were applied for 5 s via an extracellular pipette. 
Calcium transients were measured as a change in fl  uorescence   Lorenzon and Beam 381
intensity (∆F/F) using confocal imaging (excitation/emission 
parameters for fl  uo3-AM dye: 488 nm excitation, 505 nm LP 
emission fi  lter).
Whole-Cell Recording Methods
Calcium currents were recorded with the whole-cell variant of 
the patch clamp technique. Pipettes were fabricated from boro-
silicate glass and had resistances of 1.5–2.4 MΩ when fi  lled with 
internal solution (composition given above). For the measure-
ment of membrane currents, the external solution contained 
(in mM): 145 tetraethylammonium-Cl, 10 CaCl2, 10 HEPES, and 
0.003 tetrodotoxin, pH 7.4 with tetraethylammonium-OH. Test 
currents were corrected for linear components of leak and ca-
pacitative currents by digital scaling and subtraction of averaged 
control currents elicited by 20-mV hyperpolarizing steps from 
the holding potential (−80 mV). Cell capacitance was deter-
mined by integration of these same control currents and used 
to normalize test currents (pA/pF). To inactivate T-type cur-
rents and isolate L-type currents, a 1-s prepulse to −30 mV fol-
lowed by a 100-ms repolarization to −50 mV was applied before 
the test pulse.
RESULTS
Fig. 1 illustrates the constructs used, all of which contained 
BAD at one site and fl  uorescent protein at a second 
site as an independent reporter of DHPR localization. 
Except for YFP-α1S(1667-BAD)1860, these constructs were 
examined in a previous study (Lorenzon et al., 2004) and 
found able to restore electrically evoked contractions. We 
also found this to be the case for YFP-α1S(1667-BAD)1860 
expressed in α1S-null myotubes (12/13 cells). Thus, the 
incorporation of a BAD did not appear to interfere 
with the targeting or essential function of the α1S or 
β1a fusion proteins.
Streptavidin Accessibility of Targeted DHPR Sites
Our previous work (Lorenzon et al. 2004) showed that 
in fi  xed and Triton-permeabilized myotubes, strepta-
vidin had access to all of the sites illustrated in Fig. 1, 
except for BAD fused to the end of either the proxi-
mal (YFP-α1S1667-BAD) or distal (YFP-α1S1860-BAD) 
C terminus. Both of these sites were occluded in the 
presence of RyR1. An important goal of the present 
studies was to assay streptavidin accessibility under con-
ditions similar to those in vivo. As one part of this effort, 
Figure 2. In  nonfi  xed myo-
tubes, the α1S N terminus, the 
α1S proximal II–III loop, and 
the N and C terminus of β1a 
are accessible to streptavidin 
(A–D, respectively). Left pan-
els illustrate the localization 
of the YFP-DHPR fusion pro-
teins (indicated in green), 
center panels illustrate the lo-
calization of the bound strep-
tavidin (red), and right panels 
show the overlay. Bars, 5 μm.
Figure 1.  Schematic illustration of the BAD-DHPR fusion con-
structs. Constructs are designated by the sites of attachment of 
BAD (red circle) and YFP (yellow oval). In the α1S II–III loop con-
structs, α1S residues 672–685 were replaced by the BAD. For the 
α1S C terminus, BAD was attached after residue 1860, or attached 
after residue 1667, or placed after 1667 followed by α1S 1668–1860 
(YFP-α1S(1667-BAD)1860).382 Streptavidin Binding to Biotinylated DHPR Sites
nonfi  xed cells expressing the DHPR-BAD fusion proteins 
were saponin permeabilized, and then exposed to strep-
tavidin. Saponin-permeabilized myotubes retain sub-
stantial function as shown by both spontaneous Ca2+ 
release and caffeine-induced global Ca2+ release (Ward 
et al., 2000, 2001).
As in fi  xed myotubes, BAD fused to the α1S N termi-
nus was accessible in nonfi  xed myotubes to the  60-kD 
streptavidin molecule (Fig. 2 A). Specifi  cally, red fl  uor-
escent foci (center panel), representing bound strepta-
vidin, were colocalized with the foci of fl  uorescent 
protein (indicated in green, left), which report the dis-
tribution of the α1S subunit. BAD inserted into the prox-
imal region of the α1S II–III loop (replacing α1S residues 
671–686) was also accessible to streptavidin binding 
(Fig. 2 B) in nonfi  xed myotubes. A similar pattern of 
colocalizing red and green foci was present for the N and 
C termini of the β1a subunit (Fig. 2, C and D). Thus, the 
accessibility of all these sites to streptavidin was similar 
in fi  xed and nonfi  xed myotubes.
The only DHPR site that showed a difference in 
streptavidin accessibility in nonfi  xed versus fi  xed my  o-
tubes was the proximal portion of the α1S C terminus. 
In fi  xed dysgenic myotubes (Lorenzon et al., 2004), 
both the distal α1S C terminus (YFP-α1S1860-BAD) and 
proximal, truncated α1S C terminus (YFP-α1S1667-BAD) 
were inaccessible to streptavidin. In nonfi  xed cells, 
the distal α1S C terminus (YFP-α1S1860-BAD) was also 
in  accessible. The lack of accessibility is illustrated in 
Fig. 3 A, where YFP-α1S1860-BAD and streptavidin 
puncta did not co  localize (especially apparent in the 
overlay image, right). However, in distinction to fi  xed 
myotubes, the proximal, truncated α1S C terminus 
(YFP-α1S1667-BAD) was at least partially accessible 
in nonfixed myotubes (see both the presence and 
  absence of streptavidin puncta colocalized with the 
YFP puncta in Fig. 3 B). To investigate this partial ac-
cessibility further, we examined streptavidin binding 
to BAD inserted at the identical, proximal position, 
but followed by the additional, C-terminal sequence, 
YFP-α1S(1667-BAD)1860. The presence of this addi-
tional C-terminal sequence caused BAD at residue 
1667 to be accessible to streptavidin in nonfi  xed myo-
tubes (Fig. 3 C).
Table I summarizes the extent of colocalization be-
tween streptavidin binding and clusters of DHPRs. The 
fi  rst data column presents the judgment of the authors, 
based on identifi  ed images. The majority of these same 
images were also randomly assembled and presented 
unidentifi  ed to four individuals who assigned each image 
a numerical value of 0 (<5% colocalization), 1 (5–95% 
colocalization), or 2 (>95% colocalization). The mean 
values for these scores are presented in Table I, data 
column 2, and agree well with the authors’ assessment 
of identifi  ed images.
TABLE I
Streptavidin Colocalization and Accessibility to Various DHPR Sites 
in Nonfi  xed Myotubes
DHPR/BAD construct
# cells exhibiting 
colocalization Colocalization score
BAD-β1a-YFP 12 (12) 1.9 (11)
YFP-β1a-BAD 16 (16) 1.8 (11)
BAD-α1S-YFP 13 (13) 1.8 (7)
α1S(671-BAD-686)-YFP 12 (12) 1.7 (10)
YFP-α1S1860-BAD 1a (23) 0.1 (12)
YFP-α1S1667-BAD 30a (39) 0.8 (17)
YFP-α1S(1667-BAD)1860 21 (21) 1.9 (12)
The total number of cells examined for each construct noted in parentheses.
aThe YFP-α1S1860-BAD and YFP-α1S1667-BAD cells exhibited partial colo-
calization (considerably fewer dots were colocalized compared to the 
other constructs).
Figure 3.  Differential accessibility of α1S C-terminal sites to 
streptavidin in nonfi  xed myotubes. (A) Myotubes expressing YFP-
α1S1860-BAD did not display binding of streptavidin that co  lo  cal-
ized with loci of fl  uorescent DHPRs. (B) Myotubes expressing 
YFP-α1S1667-BAD displayed incomplete colocalization between 
loci of DHPRs and streptavidin binding. The arrow indicates a 
cluster of DHPRs with substantial binding of streptavidin, and 
the arrowhead a cluster of DHPRS showing very little binding of 
streptavidin. (C) Nearly complete colocalization was observed for 
YFP-α1S(1667-BAD)1860. Bars, 5 μm.  Lorenzon and Beam 383
Functional Impact of Streptavidin Binding
The ability of streptavidin to bind at DHPR sites in 
nonfi  xed myotubes raises the question of whether the 
addition of this large mass interferes with the function 
of the DHPR as the voltage sensor for EC coupling. 
To address this question, saponin permeabilization was 
not an appropriate method of applying streptavidin, 
which was introduced instead by intracellular micro-
injection. For this approach, it was important to deter-
mine (a) whether injected streptavidin could diffuse 
and bind to DHPR sites within intact myotubes, and 
(b) whether injected streptavidin interferes with the 
function of normal myotubes. Fig. 4 A1 demonstrates 
that injected streptavidin (1 mg/ml) uniformly fi  lled a 
large myotube within 1 h after injection. To determine 
if this period of time was also sufficient for binding, 
it was necessary fi  rst to release unbound streptavidin 
from the cell, which was accomplished by saponin 
permeabili  zation. Fig. 4 A2 shows for a normal myotube 
(which lacks DHPR-BAD fusion protein) that virtually 
no unbound streptavidin remains following this per-
meabilization. Fig. 4 (B and C) illustrates myotubes 
expressing either BAD-α1S-YFP or YFP-β1a-BAD, which 
were injected with streptavidin and 1 h later subjected 
to saponin permeabilization. The colocalization of red 
and green foci indicates that streptavidin binding had 
occurred during the previous 1-h incubation. As a fi  nal 
control experiment, normal myotubes were tested for 
EC coupling 2–5 h after injection of streptavidin. Extra-
cellular stimulation of such myotubes elicited brief, strong 
contractions (29/29 cells; unpublished data).
To test the effects of streptavidin binding on EC cou-
pling, individual dysgenic or β1-null myotubes express-
ing DHPR/BAD fusion constructs were initially tested 
for electrically evoked contractions before streptavidin 
injection (Fig. 5, top). At least 2 h after injection, the 
identifi  ed cells were retested for evoked contractions 
(Fig. 5, bottom). Evoked contractions were not affected 
by streptavidin binding to the N or C terminus of β1a 
(10/11 and 18/20 cells contracted, respectively) or to 
the α1S N terminus (10/11 cells). However, binding of 
streptavidin to the proximal portion of the α1S II–III 
loop abolished evoked contractions (Fig. 5, weak con-
traction in 1/12 cells; no contractions in the remainder). 
Thus, the II–III loop was the only DHPR site at which 
the additional mass of streptavidin interfered with 
EC coupling.
Electrically evoked contractions require that a brief 
depolarization produce substantial Ca2+ release. Thus, 
a partial reduction of Ca2+ release might account for 
the loss of electrically evoked contractions after strepta-
vidin binding to the proximal II–III loop. To test this, 
we examined Ca2+ release in response to a more 
  prolonged depolarization produced by application of 
80 mM KCl. Fig. 6 (top) shows that Ca2+ released by a 
5-s depolarization was reduced to a nearly undetect-
able level by streptavidin binding to the proximal II–III 
loop. This nearly complete suppression of EC coupl-
ing was not a consequence of depletion of SR Ca2+ 
stores or a direct effect of streptavidin on RyR1. Specifi  -
cally, Fig. 6 (bottom) shows that Ca2+ release in re-
sponse to the RyR agonist, 4-CmC, was not obviously 
different in streptavidin-injected, α1S(671-BAD-686)-YFP–
expressing myotubes.
In principle, the binding of streptavidin to the α1S 
II–III loop could have prevented a specifi  c conforma-
tional change necessary for EC coupling without af-
fecting other functions of the DHPR. Alternatively, 
this binding could have induced a widespread distor-
tion of α1S that abolished function of the DHPR more 
globally. Fig. 7 illustrates calcium currents in myotubes 
expressing α1S(671-BAD-686)-YFP that were injected 
Figure 4.  Diffusion and binding of streptavidin injected into 
living myotubes. (A1) 1 h after streptavidin (SA) injection of 
a normal myotube, diffuse red fl  uorescence could be observed 
throughout the cell. (A2) In the absence of DHPR-BAD fusion 
proteins, injected streptavidin is rapidly released after saponin 
permeabilization. 1 h after SA injection of a normal myotube, 
saponin was applied and an image obtained  15 min later with 
laser intensity, detector/amplifi  er gains, and offset set to be the 
same as for the images in B. (B) A 1-h period was suffi  cient to 
allow binding of injected streptavidin to BAD-α1S-YFP expressed 
in a dysgenic myotube. Nonbound streptavidin was released 
by saponin permeabilization. Bars, 5 μm. (C) Colocalization of 
red and yellow fl  uorescent puncta from injected streptavidin-
rhodamine and YFP-β1a-BAD in a β1-null myotube. Note that 
BAD-β1a-YFP streptavidin binding has not yet been confi  rmed 
by confocal imaging.384 Streptavidin Binding to Biotinylated DHPR Sites
with streptavidin. Streptavidin had no obvious effect on 
either the voltage dependence or amplitude of Ca2+ 
currents in these cells. The average peak amplitude of 
currents in α1S(671-BAD-686)-YFP–expressing cells was 
similar whether or not streptavidin was injected (Fig. 
7 B) and comparable to that of dysgenic myotubes ex-
pressing α1S-YFP (Bannister and Beam, 2005). Thus, the 
ability of α1S(671-BAD-686)-YFP to function in EC cou-
pling was eliminated by streptavidin binding, whereas 
its function as a calcium channel and its retrograde reg-
ulation from RyR1 were not affected. Although not sys-
tematically examined, we also found no obvious effect 
of injected streptavidin on Ca2+ currents in myotubes 
expressing YFP-β1a-BAD, BAD-β1a-YFP, or BAD-α1S-YFP 
(unpublished data).
DISCUSSION
In this paper, we have examined the consequences of 
applying streptavidin to myotubes expressing DHPRs 
with targeted sites of biotinylation. Except for the α1S C 
terminus, all other DHPR sites examined, including the 
α1S N terminus and proximal II–III loop and the β1a N 
and C termini, were accessible to streptavidin binding 
and showed equivalent accessibility in nonfi  xed myo-
tubes as found previously (Lorenzon et al., 2004) for 
fi  xed cells. However, the accessibility of the α1S C termi-
nus differed between fi  xed and nonfi  xed cells and de-
pended on the location of the BAD, the length of the 
C terminus, and the presence or absence of RyR1. In ad-
dition to examining accessibility, we also characterized 
the functional consequences of streptavidin binding at 
sites of the α1S and β1a subunits. Excitation–contraction 
coupling was abolished by streptavidin binding to the 
proximal portion of the α1S II–III loop, but was un-
affected by binding at the α1S N terminus or β1a N or 
C terminus.
Streptavidin Accessibility
Except for the α1S C terminus, all other sites of α1S and 
β1a showed equivalent accessibility in fi  xed and non-
fixed cells. The ability of streptavidin to bind to the 
C terminus appears to depend on the location of the 
BAD within the C terminus, the length of the C terminus, 
Figure 5. Excitation-contraction  coupling  is 
abolished by streptavidin binding to the prox-
imal portion of the α1S II-III loop, but is unaf-
fected when binding occurs at the α1S N 
terminus or β1a N or C terminus. Electrically 
evoked contractions are shown for intact 
β1-null myotubes expressing YFP-β1a-BAD or 
BAD-β1a-YFP, or dysgenic myotubes express-
ing BAD-α1S-YFP or α1S(671-BAD-686)-YFP. 
Prior to streptavidin injection, myotubes re-
sponded to extracellular stimulation with ro-
bust contractions (top). 2–4 h after streptavidin 
injection, the same individual myotubes were 
tested for their responses to identical stimula-
tion (bottom). Vertical scale, arbitrary units. 
For BAD-β1a-YFP–expressing cells, streptavi-
din binding following injection has not yet 
been confi  rmed by confocal imaging.
Figure 6.  Effect of streptavidin binding to 
the proximal α1S II–III loop on depolariza-
tion- and 4-CmC–induced Ca2+ transients. 
Representative responses are shown for nor-
mal myotubes (A) and SA-injected α1S(671-
BAD-686)-YFP–expressing myotubes (B) to 
a 5-s application of either 80 mM KCl (top) or 
0.5 mM 4-CmC (bottom). ∆F/F scale bar = 
0.4 or 0.6 for the KCl responses of the nor-
mal and SA-injected myotubes, respectively, 
and 1.0 or 0.6 for the 4-CmC responses 
of the normal and SA-injected myotubes, 
respectively. (C) Summary of peak ∆F/F am-
plitudes for KCl (top) and 4-CmC (bottom) 
responses of either normal myotubes (Norm) 
or SA-injected α1S(671-BAD-686)-YFP–ex-
pressing myotubes (SA-inj).  Lorenzon and Beam 385
and the presence of RyR1. The distal C terminus (resi-
due 1860) is not accessible in either fi  xed or non  fi  xed 
cells, suggesting that this region may be buried. How-
ever, the accessibility of the proximal C terminus 
(residue 1667) is more complex. The BAD is partially 
accessible when attached at the end of a truncated 
(after residue 1667) C terminus in nonfi  xed myotubes 
(Fig. 3 B), but inaccessible in fi  xed myotubes (Lorenzon 
et al., 2004). Our data do not allow us to differentiate 
between the possibilities that the proximal α1S C terminus 
is partially accessible in all junctions or ranges from 
accessible to inaccessible, perhaps as a consequence of 
developmental maturity of the junctions. In either case, 
it is necessary to suppose that fi  xation reduces the par-
tial accessibility of the proximal α1S C terminus to below 
the level of detection.
The partial accessibility of the proximal α1S C terminus 
in nonfi  xed myotubes could also refl  ect the existence of 
two, functionally distinct conformations, one of which 
is occluded by RyR1 and one which is not. If the frac-
tional occupancy of the nonoccluded state was only a 
few percent, nearly all sites would be occluded after 
fi  xation. Furthermore, the binding of streptavidin in 
nonfi  xed cells would gradually trap the proximal C ter-
minus in the nonoccluded conformation, resulting in 
partial colocalization of streptavidin with junctional 
DHPRs. However, BAD attached at the identical, proxi-
mal site (1667) within a longer C terminus (BAD followed 
by α1S residues 1668–1860) was accessible to strepta  -
vidin in nonfi  xed myotubes (Fig. 3 C), suggesting that the 
distal C terminus may anchor the proximal C terminus 
in a nonoccluded conformation.
The pattern of streptavidin accessibility to DHPR sites 
is in good agreement with a previous study using the 
complementary approach of measuring the fl  uorescence 
resonance energy transfer (FRET) effi  ciency of a CFP-
YFP tandem attached to these same sites of DHPRs 
within junctions that either did, or did not, contain 
RyR1 (Papadopoulos et al., 2004). In that FRET study, a 
difference in FRET was taken as an indication that the 
presence of RyR1 impacted the environment of the at-
tachment site. In agreement with the present work, the 
Figure 8.  Possible mechanisms for how binding of streptavidin to 
the α1S II-III loop could interfere with EC coupling. (A) During 
normal EC coupling, membrane depolarization induces a confor-
mational change in the α1S II–III loop, which causes the activation 
of RyR1 (indicated by “starburst”) and release of calcium. The in-
serted BAD (red circle) is proximal to the “critical domain” (pink) 
and does not interfere with these events. (B) Binding of streptavidin 
could globally distort α1S such that the channel protein becomes 
nonfunctional. This possibility appears to be excluded since strep-
tavidin binding did not affect the amplitude or gross voltage de-
pendence of calcium currents. (C) Binding of streptavidin could 
interfere with the RyR1-activating conformational change of the 
II–III loop or another cytoplasmic portion of the DHPR.
Figure 7.  Streptavidin binding to the proximal portion of the α1S 
II–III loop has little effect on calcium currents. (A) Currents were 
recorded from a dysgenic myotube expressing α1S(671-BAD-686)-
YFP that was injected with streptavidin-rhodamine >2 h before 
recording. The plot shows the I-V relationship for α1S(671-BAD-
686)-YFP currents following streptavidin injection. (B) The aver-
age amplitudes of calcium currents evoked by a 200-ms voltage 
step to +40 mV from α1S(671-BAD-686)-YFP–expressing myotubes 
that were not (−SA, n = 4 cells) or were (+SA, n = 8 cells) in-
jected with streptavidin.386 Streptavidin Binding to Biotinylated DHPR Sites
FRET efficiency was equivalent in the presence and 
absence of RyR1 when the reporter was attached to the 
α1S N terminus and proximal II–III loop, and to the β1a 
C terminus. The two methods were also in quite good 
agreement for the α1S C terminus truncated at 1667, 
where the presence of RyR1 resulted in incomplete ac-
cessibility to streptavidin and reduced CFP-YFP FRET. 
The β1a N terminus was the only site for which the two 
methods gave different results in that the presence of 
RyR1 did not prevent streptavidin accessibility but did 
alter CFP-YFP FRET. One could imagine that the β1a N 
terminus is close to RyR1 but that biotin projects from 
the attached BAD in an orientation that allows strepta-
vidin accessibility.
The proximal C-terminal site examined in our studies 
(residue 1667) lies near the site at which naturally oc-
curring, proteolytic cleavage has been reported to cause 
truncation of  95% of α1S in adult skeletal muscle 
(De Jongh et al., 1991; Hulme et al., 2005). With respect 
to the distal site (residue 1860) examined in the present 
study, it is important to note that a much larger frac-
tion ( 30%) of α1S in cultured myotubes is full length 
(Shulman, 1996). Moreover, Catterall and colleagues 
(Hulme et al., 2005) propose that the A-kinase anchoring 
protein, AKAP15, anchors the cleaved portion of the 
C terminus to the proximal portion. In any case, there is 
good evidence that a large fraction of α1S in myotubes has 
the distal C terminus attached (Flucher et al., 2000a), al-
though the nature of this attachment remains unclear.
A number of possible roles have been ascribed to the 
C-terminal tails of L-type Ca2+ channels. In particular, 
portions of the C terminus of α1C (Gao et al., 2000) and 
α1S (Proenza et al., 2000) may be important both for 
traffi  cking to the plasma membrane, and for targeting 
to plasma membrane junctions with the SR (Flucher 
et al., 2000b; Proenza et al., 2000). Moreover, biochemi-
cal studies have suggested that the C-terminal residues 
1393–1527 of α1S bind calmodulin and can bind to RyR1 
(Sencer et al., 2001). Additionally, both the α1S C termi-
nus (residues 1431–1435) and RyR1 contain consensus 
binding sites for Homer (Xiao et al., 2000). Perhaps the 
direct or indirect linkage of α1S C-terminal residues to 
RyR1 has the consequence that the distal C terminus of 
α1S is inaccessible to streptavidin in RyR1-containing 
junctions, either because RyR1 directly occludes the 
distal C terminus or because the RyR1-induced arrange-
ment of DHPRs into tetrads results in occlusion.
Functional Impact of Streptavidin Binding: Direct Evidence 
that EC Coupling Depends on a Conformational Change 
Involving the α1S II–III Loop
Previous work has implicated a variety of DHPR sites as 
important for EC coupling, including the II–III loop 
critical domain and the III–IV loop of α1S and the C ter-
minus of the β1a. In particular, studies using expres-
sion in myotubes null for α1S or β1a have shown that 
mutations and/or deletions within the aforementioned 
regions profoundly affect EC coupling (Nakai et al., 
1998; Beurg et al., 1999; Ahern et al., 2001; Sheridan 
et al., 2003; Kugler et al., 2004). A priori, these regions 
could be directly involved in protein–protein interac-
tions linking DHPRs to RyRs, but they could equally 
well impact the ability of other regions of the DHPR to 
participate in such interactions. Additionally, current 
candidate regions of the DHPR could either be involved 
in static interactions that link DHPRs to RyRs, or actively 
undergo conformational changes that are essential for 
propagating the EC coupling signal. Unfortunately, the 
functional analyses to date do not provide a basis for 
distinguishing these possibilities.
Here we have found that excitation–contraction cou-
pling is abolished by streptavidin binding to the prox-
imal portion of the α1S II–III loop, but is unaffected 
when binding occurs at the α1S N terminus or β1a N or 
C terminus. Fig. 8 illustrates a model of EC coupling 
together with mechanisms by which streptavidin bind-
ing could interfere with this coupling. In particular, EC 
coupling is pictured (Fig. 8 A) as dependent upon a 
conformational change of the α1S II–III loop with the 
result that the critical domain (residues 720–765, pink) 
contacts RyR1 and activates it to release Ca2+ from 
the SR. Conceivably, the binding of streptavidin to the 
proximal II–III loop could distort the overall structure 
of the DHPR so as to entirely abolish the function of 
this protein (Fig. 8 B). This possibility would appear 
to be excluded by the result that calcium currents are 
unaffected by the binding of streptavidin to the II–III 
loop. Importantly, the amplitude of DHPR Ca2+ cur-
rent depends not only on the structural integrity of 
the DHPR but also on a retrograde functional inter-
action between RyR1 and the DHPR (Nakai et al., 1996). 
This retrograde interaction is abolished by structural 
alterations of the critical domain of the α1S II–III loop 
(Grabner et al., 1999; Kugler et al., 2004). Thus, the 
fact that Ca2+ current amplitude was unaffected by 
streptavidin binding to the proximal II–III loop pro-
vides additional support that this binding does not sig-
nifi  cantly distort the spatial interrelationship between 
the DHPR and RyR1.
As an alternative to a global disruption of structure, 
bound streptavidin could specifi  cally obstruct confor-
mational changes of DHPR cytoplasmic domains re-
quired for EC coupling. As shown in Fig. 8 C, streptavidin 
bound to the proximal II–III loop interferes with the 
conformational change that causes the downstream, 
critical domain to contact RyR1. An alternative possibil-
ity is that the critical domain contacts RyR1 at rest and 
that bound streptavidin prevents a torsional conforma-
tional change that is necessary for activation of Ca2+ 
release. In any case, our results provide the most direct 
evidence to date that conformational changes of the 
α1S II–III loop are critical for EC coupling, but do not   Lorenzon and Beam 387
preclude the possibility of additional, important confor-
mational changes of other DHPR cytoplasmic domains.
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